Mailed Outreach Program Increases Ultrasound Screening of Patients With Cirrhosis for Hepatocellular Carcinoma

Gastroenterology

Volumn 152, Issue 3, 2017, Pages 608-615.e4

  Singal, Amit G ^a,b,c,d   Tiro, Jasmin A ^b,c   Marrero, Jorge A ^a   McCallister, Katharine ^b   Mejias, Caroline ^b   Adamson, Brian ^b   Bishop, Wendy Pechero ^b,c   Santini, Noel O ^d   Halm, Ethan A ^a,b,c,d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d PARKLAND HEALTH AND HOSPITAL SYSTEM   (United States)

Author keywords

Intervention; Liver Cancer; Prevention; Randomized Controlled Trial

Indexed keywords

ASPARTATE AMINOTRANSFERASE;

ADULT; AGED; ARTICLE; CANCER SCREENING; CAUCASIAN; CLINICAL TRIAL; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DIAGNOSTIC TEST ACCURACY STUDY; ECHOGRAPHY; FEMALE; HEALTH CARE SYSTEM; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS C; HUMAN; ICD-9; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PATIENT CARE; PATIENT EDUCATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SOCIAL STATUS; THROMBOCYTE; YOUNG ADULT; AFRICAN AMERICAN; DIAGNOSTIC IMAGING; EARLY CANCER DIAGNOSIS; ETHNIC GROUP; HISPANIC; LIVER TUMOR; MINORITY GROUP; MOTIVATIONAL INTERVIEWING; PATIENT PARTICIPATION; POSTAL MAIL; PROCEDURES; REMINDER SYSTEM; SOCIAL CLASS; TELEPHONE; TEXAS; VERY ELDERLY;

ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; EARLY DETECTION OF CANCER; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MINORITY GROUPS; MOTIVATIONAL INTERVIEWING; PATIENT EDUCATION AS TOPIC; PATIENT NAVIGATION; PATIENT PARTICIPATION; POSTAL SERVICE; PROSPECTIVE STUDIES; REMINDER SYSTEMS; SOCIAL CLASS; TELEPHONE; TEXAS; ULTRASONOGRAPHY; YOUNG ADULT;

EID: 85010711876     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.10.042     Document Type: Article

References (40)

1. 1 El-Serag, H.B., Rudolph, K.L., Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132 (2007), 2557–2576.
2. 2 Rahib, L., Smith, B.D., Aizenberg, R., et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74 (2014), 2913–2921.
3. 3 Ryerson, A.B., Eheman, C.R., Altekruse, S.F., et al. Annual report to the nation on the status of cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer 122 (2016), 1312–1337.
4. 4 Zhang, B.H., Yang, B.H., Tang, Z.Y., Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130 (2004), 417–422.
5. 5 Singal, A.G., Pillai, A., Tiro, J., Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med, 11, 2014, e1001624.
6. 6 Bruix, J., Sherman, M., Management of hepatocellular carcinoma: an update. Hepatology 53 (2010), 1–35.
7. 7 Bruix, J., Sherman, M., Llovet, J.M., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35 (2001), 421–430.
8. 8 Singal, A.G., Yopp, A., Skinner, C., et al. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. J Gen Intern Med 27 (2012), 861–867.
9. 9 Singal, A.G., Li, X., Tiro, J., et al. Racial, social, and clinical determinants of hepatocellular carcinoma surveillance. Am J Med, 128, 2015, 90.
10. 10 Breen, N., Meissner, H.I., Toward a system of cancer screening in the United States: trends and opportunities. Annu Rev Public Health 26 (2005), 561–582.
11. 11 Dalton-Fitzgerald, E., Tiro, J., Kandunoori, P., et al. Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 13 (2015), 791–798.
12. 12 Gupta, S., Halm, E.A., Rockey, D.C., et al. Comparative effectiveness of fecal immunochemical test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved: a randomized clinical trial. JAMA Intern Med 173 (2013), 1725–1732.
13. 13 Gupta, S., Sussman, D.A., Doubeni, C.A., et al. Challenges and possible solutions to colorectal cancer screening for the underserved. J Natl Cancer Inst, 106, 2014, dju032.
14. 14 Genoff, M.C., Zaballa, A., Gany, F., et al. Navigating language barriers: a systematic review of patient navigators’ impact on cancer screening for limited English proficient patients. J Gen Intern Med 31 (2016), 426–434.
15. 15 Krok-Schoen, J.L., Oliveri, J.M., Paskett, E.D., Cancer care delivery and women's health: the role of patient navigation. Front Oncol, 6, 2016, 2.
16. 16 Muliira, J.K., D'Souza, M.S., Effectiveness of patient navigator interventions on uptake of colorectal cancer screening in primary care settings. Jpn J Nurs Sci 13 (2016), 205–219.
17. 17 Singal, A.G., Gupta, S., Tiro, J.A., et al. Outreach invitations for FIT and colonoscopy improve colorectal cancer screening rates: A randomized controlled trial in a safety-net health system. Cancer 122 (2016), 456–463.
18. 18 Singal, A.G., Tiro, J.A., Gupta, S., Improving hepatocellular carcinoma screening: applying lessons from colorectal cancer screening. Clin Gastroenterol Hepatol 11 (2013), 472–477.
19. 19 Singal, A.G., Yopp, A.C., Gupta, S., et al. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res (Phila) 5 (2012), 1124–1130.
20. 20 Shebl, F.M., Capo-Ramos, D.E., Graubard, B.I., et al. Socioeconomic status and hepatocellular carcinoma in the United States. Cancer Epidemiol Biomarkers Prev 21 (2012), 1330–1335.
21. 21 Jepsen, P., Vilstrup, H., Andersen, P.K., et al. Comorbidity and survival of Danish cirrhosis patients: a nationwide population-based cohort study. Hepatology 48 (2008), 214–220.
22. 22 Nehra, M.S., Ma, Y., Clark, C., et al. Use of administrative claims data for identifying patients with cirrhosis. J Clin Gastroenterol 47 (2013), e50–e54.
23. 23 Abd El Rihim, A.Y., Omar, R.F., Fathalah, W., et al. Role of fibroscan and APRI in detection of liver fibrosis: a systematic review and meta-analysis. Arab J Gastroenterol 14 (2013), 44–50.
24. 24 Willis, G.B., Cognitive interviewing: a “how to” guide. 1999, Research Triangle Institute, Research Triangle Park, Durham, NC.
25. 25 Singal, A., Volk, M.L., Waljee, A., et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 30 (2009), 37–47.
26. 26 Singal, A.G., Conjeevaram, H.S., Volk, M.L., et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev 21 (2012), 793–799.
27. 27 Kaplan, D.E., Dai, F., Aytaman, A., et al. Development and performance of an algorithm to estimate the Child-Turcotte-Pugh score from a national electronic healthcare database. Clin Gastroenterol Hepatol 13 (2015), 2333–2341 e1–e6.
28. 28 Wigg, A.J., McCormick, R., Wundke, R., et al. Efficacy of a chronic disease management model for patients with chronic liver failure. Clin Gastroenterol Hepatol 11 (2013), 850–858 e1–e4.
29. 29 Aberra, F.B., Essenmacher, M., Fisher, N., et al. Quality improvement measures lead to higher surveillance rates for hepatocellular carcinoma in patients with cirrhosis. Dig Dis Sci 58 (2013), 1157–1160.
30. 30 Beste, L.A., Ioannou, G.N., Yang, Y., et al. Improved surveillance for hepatocellular carcinoma with a primary care-oriented clinical reminder. Clin Gastroenterol Hepatol 13 (2015), 172–179.
31. 31 Singal, A., Volk, M., Rakoski, M., et al. Patient involvement is correlated with higher HCC surveillance in patients with cirrhosis. J Clin Gastroenterol 45 (2011), 727–732.
32. 32 Farvardin S, Patel J, Khambaty M, et al. Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis [published online ahead of print]. Hepatology http://dx.doi.org/10.1002/hep.28770.
33. 33 Percac-Lima, S., Ashburner, J.M., Zai, A.H., et al. Patient navigation for comprehensive cancer screening in high-risk patients using a population-based health information technology system: a randomized clinical trial. JAMA Intern Med 176 (2016), 930–937.
34. 34 Clark, P.J., Stuart, K.A., Leggett, B.A., et al. Remoteness, race and social disadvantage: disparities in hepatocellular carcinoma incidence and survival in Queensland, Australia. Liver Int 35 (2015), 2584–2594.
35. 35 Ha, J., Yan, M., Aguilar, M., et al. Race/ethnicity-specific disparities in cancer incidence, burden of disease, and overall survival among patients with hepatocellular carcinoma in the U.S. Cancer 122 (2016), 2512–2523.
36. 36 Ha, J., Yan, M., Aguilar, M., et al. Race/ethnicity-specific disparities in hepatocellular carcinoma stage at diagnosis and its impact on receipt of curative therapies. J Clin Gastroenterol 50 (2016), 423–430.
37. 37 Tan, D., Yopp, A., Beg, M.S., et al. Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States. Aliment Pharmacol Ther 38 (2013), 703–712.
38. 38 Atiq O, Tiro J, Yopp AC, et al. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis [published online ahead of print]. Hepatology http://dx.doi.org/10.1002/hep.28895.
39. 39 Patel, N., Yopp, A.C., Singal, A.G., Diagnostic delays are common among patients with hepatocellular carcinoma. J Natl Compr Canc Netw 13 (2015), 543–549.
40. 40 Singal, A.G., Waljee, A.K., Patel, N., et al. Therapeutic delays lead to worse survival among patients with hepatocellular carcinoma. J Natl Compr Canc Netw 11 (2013), 1101–1108.